Provided by Tiger Trade Technology Pte. Ltd.

X4 Pharmaceuticals Inc

4.05
+0.01000.25%
Post-market: 4.050.00000.00%19:30 EDT
Volume:299.17K
Turnover:1.21M
Market Cap:401.54M
PE:-3.27
High:4.10
Open:4.03
Low:3.94
Close:4.04
52wk High:4.83
52wk Low:2.80
Shares:99.15M
Float Shares:62.35M
Volume Ratio:0.41
T/O Rate:0.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2404
EPS(LYR):-1.8726
ROE:-113.08%
ROA:-28.15%
PB:2.58
PE(LYR):-2.16

Loading ...

BRIEF-X4 Pharmaceuticals Inc - May Offer Up To $300 Million Of Common Stock, Preferred Stock, Debt Securities, Warrants, And/Or Units - SEC Filing

Reuters
·
May 07

X4 Pharmaceuticals Inc - May Offer up to $300 Mln of Common Stock, Preferred Stock, Debt Securities, Warrants, and/or Units - SEC Filing

THOMSON REUTERS
·
May 07

X4 Pharmaceuticals net loss widens to $20.2 million in Q1 FY26; revenue drops to $2.7 million

Reuters
·
May 06

BRIEF-X4 Pharmaceuticals Q1 EPS USD -0.16

Reuters
·
May 06

X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
May 06

X4 Pharmaceuticals Q1 Operating Expenses USD 23.014 Million

THOMSON REUTERS
·
May 06

X4 says EU approves Xolremdi for WHIM syndrome treatment

Reuters
·
Apr 29

X4 Pharmaceuticals Announces European Commission Approval of Xolremdi® (Mavorixafor), the First and Only Authorized Treatment for Patients With Whim Syndrome in the European Union

THOMSON REUTERS
·
Apr 29

X4 Pharmaceuticals Inc expected to post a loss of 20 cents a share - Earnings Preview

Reuters
·
Apr 27

BRIEF-X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Apr 02

X4 Pharmaceuticals issues inducement stock options for 32,000 shares to new hires

Reuters
·
Apr 02

X4 Pharmaceuticals Inc. Announces Annual Stockholders Meeting Notice

Reuters
·
Mar 20

Analysts’ Top Healthcare Picks: X4 Pharmaceuticals (XFOR), Boston Scientific (BSX)

TIPRANKS
·
Mar 18

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Mar 17

Rpt-X4 Pharmaceuticals Q4 EPS USD -0.22

THOMSON REUTERS
·
Mar 17

X4 Pharmaceuticals Inc - Cash Runway Expected Through 2028

THOMSON REUTERS
·
Mar 17

X4 Pharmaceuticals Inc - Global 4Ward Phase 3 Chronic Neutropenia Trial on Track to Complete Enrollment in Q3 2026

THOMSON REUTERS
·
Mar 17

X4 Pharmaceuticals FY 2025 net loss widens 111.2% to USD 79.2 million as revenue rises 1,250% to USD 35.1 million

Reuters
·
Mar 17

X4 Pharmaceuticals Initiated at Buy by Guggenheim

Dow Jones
·
Mar 09

X4 Pharmaceuticals initiated with a Buy at Guggenheim

TIPRANKS
·
Mar 09